Regulatory Analysis
FDA regulatory intelligence, warning letter breakdowns, and actionable analysis for brands across all FDA-regulated categories.
Weekly FDA Roundup: April 11–17, 2026
Seven Class I device actions in three days including two tied to the same defective syringe. CDER sweeps four online pharmacies. Purolea Cosmetics Lab cited for using AI to generate compliance docs without Quality Unit review. Plus clinical trial disclosure push and a TRT label-expansion signal.
Read article →
Moringa Salmonella Outbreak 2026: Three Separate Investigations, 169 Illnesses, and a Broken Botanical Supply Chain
FDA and CDC have investigated three separate Salmonella outbreaks tied to moringa leaf powder since October 2025. 169 illnesses, 43 hospitalizations, 11 recalls in our database. Here is what every supplement brand with a botanical SKU should do now.
Read more →
Weekly FDA Roundup: April 4–10, 2026
FDA drops 7 GLP-1 warning letters in one coordinated sweep — the enforcement focus has broadened from compounders and telehealth to raw peptide vendors and eBay arbitrage sellers. Plus three device early alerts, a DSCSA fraud warning at a med spa, and a Wellcovorin NDA withdrawal.
Read more →
FDA Import Alert 66-40: What Happens When Your Drug Supplier Gets Listed
At least four foreign drug manufacturers were placed on FDA Import Alert 66-40 in Q1 2026. Here is what automatic detention without physical examination means for your supply chain and what to do before your next shipment lands.
Read more →
Weekly FDA Roundup: Oral GLP-1 approved in 50 days, CGMP cluster, and steroid-spiked supplements
Eli Lilly's Foundayo became the first new molecular entity approved under the FDA's CNPV pilot — 50 days, 294 days ahead of its PDUFA date. Three CGMP warning letters landed the same day, and a supplement recall surfaced undeclared prescription steroids in weight-gain capsules. March 27 to April 3, 2026.
Read more →
Weekly FDA Roundup: Hospital Drug Mix-Up, Natural Dye Delays, and a Cancer "Vaccine" Warning — Week of March 21–28, 2026
Amneal Pharmaceuticals recalls magnesium sulfate pouches after a tranexamic acid mix-up reaches hospitals nationwide. FDA delays beetroot red and spirulina extract approvals indefinitely. ImmunityBio warned over "cancer vaccine" claims for bladder cancer drug ANKTIVA. Plus six warning letters, two Class I device recalls, and two rare pediatric drug approvals.
Read more →
FDA Pharmaceutical Data Integrity Enforcement in 2026: Falsified Records, Destroyed Evidence, and the Import Alert That Follows
Five FDA warning letters in Q1 2026 cite deliberate falsification across drug manufacturers, contract labs, and CROs — including records destroyed while investigators were on-site. Here is what it means for US companies sourcing from overseas.
Read more →
Weekly FDA Roundup: Higher-Dose Wegovy Fast-Tracked, Device Recalls Report Injuries and a Death, Week of March 14-20, 2026
Higher-dose Wegovy approved in 54 days via the CNPV program. Two device recalls tied to 22 injuries and one death. Made Fresh Salads pulls 14 cream cheese products for Listeria. Plus 11 warning letters.
Read more →
FDA's Undeclared Prescription Drug Problem: Two Supplement Categories, One Accelerating Enforcement Pattern
Ten enforcement actions in ten weeks. That is the pace at which FDA has moved against dietary supplements containing undeclared prescription drug ingredients in 2026. Recalls, safety alerts, import holds — the activity spans two distinct product categories, involves a short list of recurring pharmaceutical compounds, and points toward continued escalation.
Read more →
Weekly FDA Enforcement Roundup — March 6–13, 2026
13 warning letters. A new draft guidance on 483 responses. 61 drug approvals pulled. The AEMS launch. And Novo Nordisk in the hot seat over unreported GLP-1 deaths.
Read more →
FDA Inspections in 2026: DOGE Didn't Cut Inspectors — It Cut Everything Around Them
FDA is running 36% below pre-pandemic inspection levels. DOGE's 2025 cuts to support staff, lab scientists, and travel logistics made closing that gap harder.
Read more →
FDA's 30 GLP-1 Warning Letters: The Largest Compounding Crackdown in Over a Decade
On March 3, 2026, the FDA issued 30 warning letters to telehealth companies selling compounded GLP-1s. Here's what happened, why it matters, and what QA teams should do now.
Read more →
FDA Food Additive Regulations 2026: Red No. 3 Ban, Petroleum Dye Phase-Out, BHA Safety Review, and What Food Brands Must Do Now
FDA food additive regulations are seeing their biggest overhaul in decades. Here's the current state of the Red No. 3 ban, petroleum dye phase-out, BHA safety review, and GRAS reform — with deadlines and action items for food brands.
Read more →
30 FDA Warning Letters in a Day: Inside the GLP-1 Compounding Crackdown and the Case That Sent Three Patients to the ER
The FDA issued 30 warning letters to compounded GLP-1 telehealth companies on March 3, 2026. One documented ER visits from bacterial endotoxin contamination. A deep-dive into the violations—and what every compounding pharmacy must do now.
Read more →
FDA Supplement Regulations 2026: CGMP Violations, 483 Observations, and the New Enforcement Reality
Our analysis of 7,500+ FDA enforcement actions shows supplement enforcement at a decade-high intensity. Here are the CGMP violation patterns, top 483 observations, and substances driving the most regulatory heat in 2026.
Read more →
FDA Recall List 2026: What 1,000 Recalls Reveal About the Biggest Threats to Food Safety
Our analysis of 1,000 FDA recall actions reveals the pathogens, allergens, and contaminants driving a 9-year high in food recalls — and the three patterns every food brand needs to understand.
Read more →
MoCRA Compliance in 2026: The Registration Deadline Just Passed — Here's What Comes Next
MoCRA biennial registration renewals are underway, with all first renewals due by July 1, 2026. Here's what FDA's expanded authority means for beauty brands, what safety records you must keep, and the new NSF standard that's reshaping compliance.
Read more →
FDA Recall List, March 2026: Undeclared Allergens, Hidden Prescription Drugs, and Plastic Contamination
The FDA recall list for late February and early March 2026 shows three clear patterns: an allergen labeling wave, prescription drugs in supplement products, and physical contamination at scale.
Read more →
Nobody Monitors the FDA for Your Specific Products. We Built the Thing That Does.
MoCRA renewals, PFAS evaluations, warning letters up 73%. The information is public. The question is whether you know which of YOUR products any of it affects. That cross-reference step is where warning letters live — and nobody automates it. Until now.
Read more →
Weekly FDA Roundup: Compounding Crackdown and Device Safety Alerts — Week of Feb 21–28, 2026
55 FDA actions in one week: a landmark framework for ultra-rare genetic disease therapies, a compounding pharmacy warning letter previewing the GLP-1 enforcement surge, four medical device safety alerts from four manufacturers, and two recalls for undeclared prescription drugs in supplements.
Read more →
Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026
FDA revokes the US-EU pharmaceutical GMP mutual recognition agreement effective March 23, while a blood glucose correction links 114 injuries and one death to an error-code flaw, and five simultaneous Class I recalls sweep a hummus brand.
Read more →
Weekly FDA Roundup: Hormone Therapy Gets a New Label, Botulism Stalks the Supplement Aisle — Week of Feb 7–14, 2026
FDA removed MHT boxed warnings, approved a first-of-its-kind pancreatic cancer device, launched a BHA reassessment, and fielded 51 recalls — including a 12-SKU Clostridium botulinum sea moss gel cluster.
Read more →
Weekly FDA Roundup: GLP-1 Crackdown, Abbott's Triple Hit, and the Artificial Colors Pivot — Week of Jan 31–Feb 7, 2026
FDA signals the end of the GLP-1 compounding era, Abbott Diabetes Care faces three enforcement actions in 48 hours, and new artificial color policy clears the path for natural alternatives.
Read more →
Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026
FDA's week of Jan 24–31 brought 35 actions: a warning letter targeting a pediatric blood lead testing device with false positives, four FSVP letters in one day, and 22 recalls dominated by allergen and labeling failures.
Read more →
Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026
FDA issued a MAHA-driven gluten labeling RFI, reported ImportShield efficiency gains, and posted five warning letters — alongside 28 recalls and a serious wound care device alert from Integra LifeSciences.
Read more →
Weekly FDA Roundup: Pecorino Romano Class I Recall Sweep and CGT Flexibility Shift — Week of Jan 10–17, 2026
A coordinated 8-product Class I recall from Ambriola Co. swept multiple Pecorino Romano brands; FDA formalized CMC flexibility for cell and gene therapies under Commissioner Makary.
Read more →
Weekly FDA Roundup: Supplement Adulteration, CGMP Cluster, and Nicotine Pouch Crackdown — Week of January 3–10, 2026
FDA opened 2026 with a targeted enforcement week: a dietary supplement recalled for undeclared meloxicam, three CGMP warning letters to OTC manufacturers on the same day, and two tobacco retailers cited for unauthorized nicotine pouches.
Read more →
Weekly FDA Roundup: PFAS in Cosmetics, a Children's Supplement Spiked with an Unapproved Drug, and a Holiday Recall Wave — Week of Dec 27–Jan 3
FDA's MoCRA report finds insufficient safety data for most PFAS in cosmetics; a children's growth supplement contained hidden ibutamoren; seven herbal products recalled in one sweep.
Read more →What if this analysis was about YOUR products?
Policy Canary monitors the FDA for your specific products — by name, by ingredient, by facility. Start your free trial.
Start Free Trial